Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities

Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge f...

Descripción completa

Detalles Bibliográficos
Autores principales: Porru, Manuela, Pompili, Luca, Caruso, Carla, Biroccio, Annamaria, Leonetti, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850913/
https://www.ncbi.nlm.nih.gov/pubmed/29534749
http://dx.doi.org/10.1186/s13046-018-0719-1
Descripción
Sumario:Developing drugs that target KRAS, the most frequently mutated oncogene in cancer, has not been successful despite much concerted efforts dedicated towards it in the last thirty years. Considering the key role this driver oncogene plays, the pharmacological drugging of KRAS remains a key challenge for cancer research. In this review, we highlight the emerging experimental strategies for blocking KRAS function and signaling and its direct targeting. We also report on the results in this field of research produced by our group.

Ejemplares similares